• Embed Doc
  • Copy Link
  • Readcast
  • Collections
  • CommentGo Back
Download
 
Compilation abstracts which have been approved to be presented at
1) CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD) AND EMPHYSEMAControl/Tracking Number:
2009-O-419-ISSCR
Activity:
Oral
Current Date/Time:
2/22/2009 1:44:03 PM
IMPROVEMENT OF COPD AND EMPHYSEMA WITH AMINISTRATION OFUNFRACTIONS AUTOLOGOUS BONE MARROW ( WORLD PIONEER EXPERIENCEFROM ARGENTINA)Author Block 
 
Fernandez Vina, Roberto
1
, Saslvsky, Jorge
2
, Andrin, Oberdan
3
,Vrsalovic, Francisco
1
, Fernandez Vina, Federico
1
, Camozzi, Liliana
3
, Ferreira da SilvaLima, Janaina
41
Stem cels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentinaand Maimonides University Buenos Aires Argentina, Buenos Aires, Argentina,
2
Stem celstherapy and Interventional Cardiology, Medicine School University of Rosario Argentina,Rosario, Argentina,
3
Stem cels therapy and Interventional Cardiology, Fernandez VinaFoundation Argentina & San Nicolas Private Hospital, Buenos Aires, Argentina,
4
Stemcels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentina,Buenos Aires, Argentina
 Abstract:
Objetives:
To present the firsts reports and follows up from Argentina of 33 patients,who carry severe chronic obstructive pulmonary disease Emphysematous kind treatedwith
 
Unfractions Autologous Bone Marrow
, All patients have a smoking history for30-40 years, quit smoking since 6 years ago. Using oxygen 2 lpm 24/7, Ipratropium,nebulizaded Salbuterol , prednison. Grade III-IV short of breath.
Material and Methods:
Laboratory Data: Forced vital capacity: 0.5 l (12%), VEF1:0,30 l (10%) y 0,42 l (13%) post-bronchiodilator, FEF 25-75: 0,14 l/sec(8%), MVV: 11l/min(10%); TLC: 2.90 l/min (46%), Diffusion Capacity: 10.2 ml/mmHg/min (64%).Thepatients were submitted to a procedure to extract 600 ml of bone marrow, thatpresented: Total cells 9184 x10p6/ ml, Total mononuclears 3218 x10p6/ml, CD34+: 4,8x10p6/ml, CD34+CD38-: 0,72 x10p6/ml. Using IV infusion, in a rhythm of infusion of 300 ml/h .
Evolution and Results:
After 60 days of the procedure all the patients weresubmitted to clinical and laboratorial controls, which presented: Saturation 95-97% inroom air, while exercising, free of oxygen. Dispnea Grade 2, decreased of the requiredmedication to 1 Salbuterol nebulization per day in all cases and 12 of them with 1doses of Ipratropio per day, All patients decreased the doses of prednisone and finallyquit with this medication totally. Laboratory data: Forced Vital Capacity: 1,94 l , VEF1:
 
0,69 l y 0,88 l, FEV25-79: 0,38 l/sec, MVV: 58 l/min, TLC is normal, Diffusion Capacity isNormal.
Conclusions:
The autologous adult stem cell from
Unfractions Autologous BoneMarrow
implanted in lung improve the pulmonary function in patients at less in lungterminal diseases.
2) HEARTH CONDITIONS – CHRONIC MYOCARDIAL ISCHEMIA AND MYOCARDIALINFARCTIONControl/Tracking Number:
2009-O-417-ISSCR
Activity:
Oral
Current Date/Time:
2/22/2009 1:43:21 PM
ADMINISTRATION OF UNFRACTIONS AUTOLOGOUS BONE MARROW INCHRONIC CORONARY DISEASE ( ARGENTINA PIONEER EXPERIENCE)Author Block 
 
Fernandez Vina, Roberto J.
1
, Saslavsky, Jorge
2
, Andrin, Oberdan
3
,Vrsalovic, Francisco
3
, Fernandez Vina, Federico
4
, Camozzi, Liliana
5
, Ferreira da SilvaLima, Janaina
4
, Murad Neto, Stans
6
, Tuma, Jorge
71
Stem cels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentinaand Maimonides University Buenos Aires Argentina, Buenos Aires, Argentina,
2
Hematology, Medicine School University of Rosario Argentina, Rosario, Argentina,
3
Stem cels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentina& San icolas Private Hospital, Buenos Aires, Argentina,
4
Stem cels therapy andInterventional Cardiology, Fernandez Vina Foundation Argentina & San Nicolas PrivateHospital, Buenos Aires, Argentina,
5
Laboratory Clinic, Fernandez Vina FoundationArgentina, Buenos Aires, Argentina,
6
Stem cels therapy and Interventional Cardiology,Instituto de Cardilogia de Post Grado Rio De Janeiro Brasil, Rio de Janeiro, Brazil,
7
Stemcels therapy and Interventional Cardiology, La Maison de Sante & San Felipe ClinicLima, Lima, Peru
Abstract:Objetives:
Unfractions Autologous Bone Marrow may be used in the treatment of chronic myocardial ischemia and myocardial infarction.
 Method :
70 patients with refractory angina or cardiac failure and no possibility of surgical revascularization were included. The age of patients (46 men and 24 women)oscillated between 53 and 71 years old. Electrocardiograms showed MI Sequel indifferent walls of the both ventricles. Echocardiograms showed extensiveMyocardiopathy with Diastoles diameter oscillating form 65 to 73mm and the FEjectionoscillating between 32% and 34%. Stress test revealed in 52 patients anterior wall andapical necrosis with severe perinecrótic ischemia; in 29 patients inferior and lateralnecrosis; and 63 multiple ischemic areas, Ventriculography revealed increment of EDVolume and ESystole Volume, with FE oscillating between 32% and 36%. The CellImplant was made by “Retrograde Injection through the Sinus Coronary Vein totallyoccluded with balloon”. The volume injected was 150cc The average of totalmononuclears cells implanted 9 x 10p8.
Follow up:
After a period of three month a progressive increase of sectors contractilitywas observed in the echocardiograms. After 180 days it was observed that FE hadimproved between 38% and 51%. Scintigraphy controls revealed improvement of theperfusion in 62 patients of the perinecrótic and diffuse ischemic areas, 65 patients were
 
subject to Ventriculography, after 360 days and it was observed that the FE improvedup to 48%.
 Conclusions:
 The injection of Unfractions Autologous Bone Marrow has demonstratedimprovement of the perfusion, surely through angiogenesis that produced the FEincrease, objectived by echocardiograms, and Ventriculography. 92% of the patients,showed an improvement of the contractility of border zone of scars. It was notobserved any progression of coronary occlusive disease after a period of 4 year.45patients have achieved 2 year of evolution and they are asymptomatic or infunctional class I-II.
3) DIABETES TYPE 1
 
Control/Tracking Number:
2009-O-416-ISSCR
Activity:
Oral
Current Date/Time:
2/22/2009 1:42:00 PM
REPORT FROM ARGENTINA OF FIRST THREE YEARS FOLLOWS UP OFAUTOLOGOUS STEM CELLS IMPLANT IN DIABETES TYPE 1 (WORLD WIDEPIONEER EXPERIENCE )Author Block 
 
Fernandez Vina, Roberto
Fernandez Vina Foundation Argentina, Buenos Aires, Argentina
Abstract:Background:
 The adult stem cells CD34 (+)CD38(-) have the capacity to differentiatein functional cells on endocrine pancreas We did the first implant of ASC in the world indiabetes 1 in 2005
 
.
 Objectives:
 To report the long time performance of Diabetic type 1 patients treatedwith Stems cells implant.
 Method:
Following the first three years on cell therapy for diabetes 1, the conclusionsare optimistic. In this study we have observed the evolution of 38 Diabetic type 1patients, 20 male, 18 female, average age 23.06 years old (±20.2). All the patientswere under insulin therapy. For the transplantation we harvested bone marrow fromiliac crest by aspiration, then the sample was processed using a density gradientseparation method, obtained 120ml (±95) of CD34(+) and CD38(-) cells solution. Forthe implant we made a procedure of catheterization through Spleen Artery. Nocomplications or further events were observed during or after the procedure. Thepatients were sent to clinical and blood samples control during the 12 months followingthe implant.
Results:
C-Peptide Basal (ng/ml), Basal 0.39 --- 6 Months 0.54 --- 36 Months 1.95 --- Increment98.30%,
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...